Prof Yi-Long Wu speaks to ecancer about early-phase results evaluating SHR-A2009, a novel HER3-directed antibody-drug conjugate, in combination with a third-generation EGFR tyrosine kinase inhibitor in patients with EGFR-mutant non-small cell lung cancer.

The combination demonstrated encouraging clinical activity in both previously treated and first-line settings, with particularly strong progression-free survival signals in treatment-naïve patients.

Safety was manageable overall, although some higher-grade adverse events, including interstitial lung disease, were observed and require careful monitoring.

These findings support further development of this combination, with a phase III trial already underway to confirm its potential as a new first-line treatment option in EGFR-mutant lung cancer.